DBI — Deutsche Biotech Innovativ AG Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- €4.78m
- €4.76m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.08 | ||
| Price to Tang. Book | 7.08 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -26.66% | ||
| Return on Equity | -24.31% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 0.2 | 0.2 | 0.22 | 0.12 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Deutsche Biotech Innovativ AG, formerly Venetus Beteiligungen AG, is a Germany-based biotechnology company. The Company focuses on the identification of relevant biomarkers in the blood of affected patients, and also develops targeted therapies to prevent septic shock and inhibit tumor growth, as well as a small molecule drug for breast cancer prevention. . Its product portfolio comprises various indicators, among others, for sepsis therapy (Adrecizumab), for breast cancer prevention (DB1RA) and for cancer therapy (AB2302). Its research and development activities are entirely conducted by project companies, in which the Company holds interest. The Company's subsidiaries include AngioBiomed GmbH, AdrenoMed AG, Oncoprevent GmbH and MyLife Diagnostics GmbH.
Directors
- Renke Luehrs CSU (62)
- Metod Miklus VSU (63)
- Andreas Bergmann MGB (61)
- Ralf Jakobs MGB
- Bernd Wegener MGB (75)
- Siegmund Karasch SUB
- Last Annual
- December 31st, 2019
- Last Interim
- June 30th, 2020
- Incorporated
- December 31st, 2009
- Public Since
- April 5th, 2012
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Frankfurt Stock Exchange
- Shares in Issue
- 947,296
- Address
- Neuendorfstrasse 15a, HENNIGSDORF, 16761
- Web
- https://www.dbi-ag.de/
- Phone
- +49 33022077824
- Auditors
- Mazars GmbH Wirtschaftsprufungsgesellschaft
Upcoming Events for DBI
Similar to DBI
4Sc AG
Frankfurt Stock Exchange
CureVac NV
Frankfurt Stock Exchange
Diagonal Bio AB
Frankfurt Stock Exchange
Elanix Biotechnologies AG
Frankfurt Stock Exchange
Medpace Holdings
Frankfurt Stock Exchange
FAQ
What is the Deutsche Biotech Innovativ AG share price?
As of Today at 01:06 UTC, shares in Deutsche Biotech Innovativ AG are trading at €11.00. This share price information is delayed by 15 minutes.
How has the Deutsche Biotech Innovativ AG share price performed this year?
Shares in Deutsche Biotech Innovativ AG last closed at €11.00 and the price had moved by -81.03% over the past 365 days. In terms of relative price strength the Deutsche Biotech Innovativ AG share price has underperformed the FTSE Global All Cap Index by -82.62% over the past year.
What are the analyst and broker recommendations for Deutsche Biotech Innovativ AG?
The overall consensus recommendation for Deutsche Biotech Innovativ AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Deutsche Biotech Innovativ AG dividend yield?
Deutsche Biotech Innovativ AG does not currently pay a dividend.
Does Deutsche Biotech Innovativ AG pay a dividend?
Deutsche Biotech Innovativ AG does not currently pay a dividend.
When does Deutsche Biotech Innovativ AG next pay dividends?
Deutsche Biotech Innovativ AG does not currently pay a dividend.
How do I buy Deutsche Biotech Innovativ AG shares?
To buy shares in Deutsche Biotech Innovativ AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Deutsche Biotech Innovativ AG?
As of the previous close price of €11.00, shares in Deutsche Biotech Innovativ AG had a market capitalisation of €10.42m.
Where are Deutsche Biotech Innovativ AG shares listed?
Here are the trading details for Deutsche Biotech Innovativ AG:
- Country of listing: Germany
- Exchange: FRA
- Ticker Symbol: DBI
What kind of share is Deutsche Biotech Innovativ AG?
Based on an overall assessment of its quality, value and momentum Deutsche Biotech Innovativ AG is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Deutsche Biotech Innovativ AG share price forecast for 2023?
The analyst consensus target price for shares in Deutsche Biotech Innovativ AG is €43.60. That is 296.36% above the last closing price of €11.00.
Analysts covering Deutsche Biotech Innovativ AG currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Deutsche Biotech Innovativ AG share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Deutsche Biotech Innovativ AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -64.51%.
As of the last closing price of €11.00, shares in Deutsche Biotech Innovativ AG were trading -81.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Deutsche Biotech Innovativ AG PE Ratio?
The Deutsche Biotech Innovativ AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €11.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Deutsche Biotech Innovativ AG?
Deutsche Biotech Innovativ AG's management team is headed by:
- Renke Luehrs - CSU
- Metod Miklus - VSU
- Andreas Bergmann - MGB
- Ralf Jakobs - MGB
- Bernd Wegener - MGB
- Siegmund Karasch - SUB